Gene Expression Profiling and its Utility in Prediction of Local Relapse after Breast-conserving Therapy in Early Breast Cancer

Cancer Genomics - Proteomics

Jocelyne Jacquemier⁵  Mohamed Benchalal⁶  Pascal Finetti²  Daniel Birnbaum³  Renaud Sabatier⁷  François Bertucci⁸  Agnes Tallet¹  Nathalie Cervera²  Gilles Houvenaeghel⁴ 

[1] Department of Radiotherapy, Institut Paoli Calmettes, Marseille, FranceDepartment of Radiotherapy, Institut Paoli Calmettes, Marseille, FranceDepartment of Radiotherapy, Institut Paoli Calmettes, Marseille, France;Department of Molecular Oncology, Marseille Cancer Research Center, Paoli Calmettes Institute, UMR891 Inserm, Marseille, FranceDepartment of Molecular Oncology, Marseille Cancer Research Center, Paoli Calmettes Institute, UMR891 Inserm, Marseille, FranceDepartment of Molecular Oncology, Marseille Cancer Research Center, Paoli Calmettes Institute, UMR891 Inserm, Marseille, France;Department of Medical Oncology, Institut Paoli Calmettes, Marseille, FranceDepartment of Medical Oncology, Institut Paoli Calmettes, Marseille, FranceDepartment of Medical Oncology, Institut Paoli Calmettes, Marseille, France;Department of Surgery, Institut Paoli Calmettes, Marseille, FranceDepartment of Surgery, Institut Paoli Calmettes, Marseille, FranceDepartment of Surgery, Institut Paoli Calmettes, Marseille, France;Department of Biopathology, Institut Paoli Calmettes, Marseille, FranceDepartment of Biopathology, Institut Paoli Calmettes, Marseille, FranceDepartment of Biopathology, Institut Paoli Calmettes, Marseille, France;Department of Radiotherapy, Eugène Marquis Center, Rennes, FranceDepartment of Radiotherapy, Eugène Marquis Center, Rennes, FranceDepartment of Radiotherapy, Eugène Marquis Center, Rennes, France;Department of Molecular Oncology, Marseille Cancer Research Center, Paoli Calmettes Institute, UMR891 Inserm, Marseille, FranceDepartment of Medical Oncology, Institut Paoli Calmettes, Marseille, FranceDepartment of Molecular Oncology, Marseille Cancer Research Center, Paoli Calmettes Institute, UMR891 Inserm, Marseille, FranceDepartment of Molecular Oncology, Marseille Cancer Research Center, Paoli Calmettes Institute, UMR891 Inserm, Marseille, FranceDepartment of Medical Oncology, Institut Paoli Calmettes, Marseille, FranceDepartment of Medical Oncology, Institut Paoli Calmettes, Marseille, FranceDepartment of Molecular Oncology, Marseille Cancer Research Center, Paoli Calmettes Institute, UMR891 Inserm, Marseille, FranceDepartment of Medical Oncology, Institut Paoli Calmettes, Marseille, France;Department of Molecular Oncology, Marseille Cancer Research Center, Paoli Calmettes Institute, UMR891 Inserm, Marseille, FranceDepartment of Medical Oncology, Institut Paoli Calmettes, Marseille, FranceUniversity of the Mediterranean, Marseille, FranceDepartment of Molecular Oncology, Marseille Cancer Research Center, Paoli Calmettes Institute, UMR891 Inserm, Marseille, FranceDepartment of Molecular Oncology, Marseille Cancer Research Center, Paoli Calmettes Institute, UMR891 Inserm, Marseille, FranceDepartment of Medical Oncology, Institut Paoli Calmettes, Marseille, FranceUniversity of the Mediterranean, Marseille, FranceDepartment of Medical Oncology, Institut Paoli Calmettes, Marseille, FranceDepartment of Molecular Oncology, Marseille Cancer Research Center, Paoli Calmettes Institute, UMR891 Inserm, Marseille, FranceDepartment of Medical Oncology, Institut Paoli Calmettes, Marseille, FranceUniversity of the Mediterranean, Marseille, FranceUniversity of the Mediterranean, Marseille, FranceDepartment of Molecular Oncology, Marseille Cancer Research Center, Paoli Calmettes Institute, UMR891 Inserm, Marseille, FranceDepartment of Medical Oncology, Institut Paoli Calmettes, Marseille, FranceUniversity of the Mediterranean, Marseille, France

关键词: Breast cancer;    local relapse;    gene expression profiling;   

DOI  :  

来源: Delinasios GJ CO

【 摘 要 】

Background: Local relapse (LR) after breast-conserving therapy (BCT) is not accurately predicted by histological/clinical factors. Gene expression profiling was used here to discover LR-associated transcriptional alterations. Materials and Methods: Gene expression profiling was carried out of 81 early breast carcinomas obtained from 30 patients who developed a LR (LR+) after BCT and 51 who did not (LR–). LR+ and LR– samples were matched for known LR risk features. Results: LR was not associated with a given molecular subtype. Supervised analysis identified a 212-gene signature, which was not validated in independent tumors. No gene set or biological pathway was differentially expressed between LR+ and LR– groups. Twelve published prognostic expression signatures failed to distinguish these groups of carcinomas. The gene expression profiles of 9 cases of LR and the corresponding primary tumors were very similar despite the delivery of radiotherapy. Conclusion: In this series, the onset of LR was not predicted by gene expression alterations.

【 授权许可】

Unknown